The latest price target for Upstream Bio (NASDAQ:UPB) was reported by JP Morgan on November 5, 2024. The analyst firm set a price target for $38.00 expecting UPB to rise to within 12 months (a possible 134.43% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Upstream Bio (NASDAQ:UPB) was provided by JP Morgan, and Upstream Bio initiated their overweight rating.

There is no last upgrade for Upstream Bio

There is no last downgrade for Upstream Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Upstream Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Upstream Bio was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest Upstream Bio (UPB) rating was a initiated with a price target of $0.00 to $38.00. The current price Upstream Bio (UPB) is trading at is $16.21, which is within the analyst’s predicted range.